F S&P 500
5,297.25 -27.50 (-0.52%) F Dow Jones
38,765.00 -179.00 (-0.46%) F Nasdaq
18,830.75 -109.75 (-0.58%) E-mini Russell 2000 Index Futur
2,058.20 -15.00 (-0.72%) Petróleo
80.40 +0.57 (+0.71%) Oro
2,348.70 -7.80 (-0.33%)
Next Science Limited (NXSCF)
Next Science Limited
Australia Square
Level 14 264-278 George Street
Sydney, NSW 2000
Australia
61 4 1229 2977
https://www.nextscience.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Harry Thomas Hall | MD, CEO & Director | 418.38k | N/D | N/D |
| Dr. Matthew Franco Myntti | Founder & CTO | 368.5k | N/D | N/D |
| Marc Zimmerman | Chief Financial Officer | 343.33k | N/D | N/D |
| Mr. Jon Swanson | Chief Operating Officer | 265.37k | N/D | N/D |
| Mr. Robert Bell | Senior Vice President of North American Sales | N/D | N/D | N/D |
| Ms. Gillian Maria Nairn AGIA, B.A., BA, L.L.B., L.L.M., LLB, LLM, MAICD | Company Secretary | N/D | N/D | N/D |
Descripción
Next Science Limited engages in the research, development, and commercialization of technologies that address the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial gel that conforms to the postoperative wound; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.
Gestión corporativa
La calificación ISS Governance QuickScore de Next Science Limited a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
